Overview

A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects

Status:
Not yet recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
This study used a single-dose, open and fixed sequence design to compare the pharmacokinetics in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Efavirenz